Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Vascular Thrombotic Events (VTEs) in the GRIFFIN Study (AFT-29)
- Citation:
- Clin Lymphoma Myeloma Leuk vol 21 (suppl 2) abstr P-180
- Meeting Instance:
- IMW 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3902
- Pharmas:
- Janssen Research & Development
- Grants:
- Corr. Author:
- Authors:
- Douglas W. Sborov Muhamed Baljevic Brandi Reeves Jacob Laubach Yvonne A. Efebera Cesar Rodriguez Luciano J. Costa Ajai Chari Rebecca Silbermann Sarah A. Holstein Larry D. Jr. Anderson Jonathan L. Kaufman Nina Shah Huiling Pei Sharmila Patel Annelore Cortoos Blake Bartlett Jessica Vermeulen Thomas S. Lin Peter M. Voorhees Paul G. Richardson
- Networks:
- CA136, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-UT003, NC002, NE003, OH008, OR013, TN008
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: